LLY
Eli Lilly and Company
LLY has lower modeled downside risk, despite its lower overall score.
ZVRA
Zevra Therapeutics, Inc.
ZVRA has a slight edge over LLY overall, supported by stronger fundamentals and stronger modeled upside.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZVRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ZVRA's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ZVRA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $7.75 | -31% |
| Current | 9.2x | $11.16 | — |
| Fair | 11x | $13.47 | +21% |
| Forward | 14x | $11.16 | — |
| Expensive | 24x | $28.69 | +157% |
Historical ranges are pointers, not guarantees.
ZVRA has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ZVRA on the outlook, with more favorable valuation expectations.
ZVRA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZVRA, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ZVRA on earnings, with more consistent year-over-year improvement.
ZVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | -32% |
| Q3 2026 | $1.21 | +227% |
| Q2 2026 | $0.94 | +$1.25 |
| Q1 2026 | $2.01 | +$4.01 |
| Q4 2025 | $1.35 | +$3.69 |
| Q3 2025 | $0.37 | +$2.37 |
| Q2 2025 | -$0.31 | +$1.40 |
| Q1 2025 | -$2.00 | -$0.62 |
| Q4 2024 | -$2.34 | -$1.02 |
ZVRA earned $1.21 per share over the past year, about three times what it earned the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ZVRA on profitability, with a higher operating margin.
ZVRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
| Q4 2024 | $12M | -8.9% |
ZVRA's revenue has grown year over year for seven quarters in a row: $38M last quarter, up 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +15 points |
| Q2 2026 | 42% | +317 points |
| Q1 2026 | 144% | +170 points |
| Q4 2025 | 27% | +155 points |
| Q3 2025 | 16% | +755 points |
| Q2 2025 | -274% | +260 points |
| Q1 2025 | -26% | +572 points |
| Q4 2024 | -128% | -17 points |
ZVRA's operating margin was 31% last quarter, up 15 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ZVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +136% |
| Q2 2026 | $16.8M | +$20.6M |
| Q1 2026 | $6.1M | +$14.4M |
| Q4 2025 | $5.5M | +$21.8M |
| Q3 2025 | $4.2M | +$22.3M |
| Q2 2025 | -$3.8M | +$15.3M |
| Q1 2025 | -$8.3M | +$7.8M |
| Q4 2024 | -$16.3M | -$20K |
ZVRA has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ZVRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ZVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +396K shares |
| 1 year | +10% | +5.8M shares |
| 3 years | +78% | +27M shares |
| 5 years | +75% | +26.5M shares |
| Available history | +3231% | +59.9M shares |
ZVRA has 62M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.4M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ZVRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q4 2021 | -14.1x | Net Cash |
| Q3 2021 | -17.3x | Net Cash |
| Q2 2021 | -15.3x | Net Cash |
| Q1 2021 | -14.1x | Net Cash |
ZVRA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ZVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 45.9 | Neutral |
ZVRA's weekly RSI is 51 (neutral) and its Stochastic is 46 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ZVRA PE vs Healthcare Sector
| Metric | ZVRA | Sector median | Relative |
|---|---|---|---|
| PE | 9.2x | 26x | 64% below |
| PE % | 40 | 29 | 11 pts above |
ZVRA has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ZVRA on trend strength, trading above more of its moving averages.
ZVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 4.8% above |
| 20 week MA | $11.3 | 1.5% below |
| 50 week MA | $10.4 | 7.3% above |
| 100 week MA | $9.66 | 16% above |
| 200 week MA | $7.72 | 45% above |
ZVRA's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ZVRA on returns for 2026, with the stronger performance.
ZVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.69 | $11.5 | +72% |
| 2021 | $11.5 | $8.97 | -22% |
| 2022 | $8.97 | $4.29 | -52% |
| 2023 | $4.29 | $6.55 | +53% |
| 2024 | $6.55 | $8.39 | +28% |
| 2025 | $8.39 | $8.87 | +5.7% |
| 2026 YTD | $8.87 | $11.2 | +26% |
ZVRA has finished higher in four of the last six years, two of them by more than 50%. It's up 26% so far in 2026.